Partnerships and collaborations enable our ability to accelerate the global investigation of novel combination
treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around
the world.
Strategic partners to advance global development and commercialization activities:
Taiho has development and commercial rights in Japan and other countries in Asia, excluding China, for domvanalimab, zimberelimab, quemliclustat, etrumadenant and casdatifan. In Japan, Taiho is operationalizing the ongoing Phase 3 PRISM-1 registrational study for quemliclustat and participating in the Phase 3 PEAK-1 registrational study for casdatifan.
Opportunities for collaboration:
CAS
Casdatifan
HIF-2𝛂 Inhibitor
ETRUMA
Etrumadenant
Adenosine A2a/A2b Receptor Antagonist